Gedea´s ambition is to develop the first antibiotic-free treatment that both treats and prevents bacterial vaginosis. pHyph is a vaginal tablet that has shown an excellent medical effect.

GEDEA BIOTECH

pHyph is developed by Gedea Biotech – a company that was set up by a multidisciplinary team from Lund University.

MEDICAL NEED

Bacterial vaginosis is a recurring problem that affects women around the world.

CLINICAL TRIALS

In our most recently concluded trial, 82% of the subjects were clinically cured of bacterial vaginosis after one week.

According to the World Health Organization (WHO), antibiotic resistance is one of the greatest threats to global health of our time. A total of 4% of all antibiotics prescribed to women in Sweden are used to treat bacterial vaginosis.1
1. Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2019.
WHO

NEWS

Gedea Biotech aims to make a sustainable contribution to global women’s health and to limit the unnecessary use of antibiotics. We develop a treatment that is safe to use, effective and free of antibiotics, to solve the problem with vaginal infections and their complications.

Annette Säfholm
+46 (0) 708 - 91 86 81
EU
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 878775